The mission of Ultrast is to exploit our innovative technology to improve diagnostic imaging, benefiting human health.

Ultrast's initial project is to commercialize our phase-shifting media (PSM) for use in ultrasound imaging of the uterus. This new (patent pending) media easily allows diagnostic ultrasound images of the uterus to have the clarity of images previously seen only during pregnancy or by using cumbersome methods.

Company founders:

Dominique de Ziegler, MD is a native of France. Dr. de Ziegler attended medical school in Geneva, Switzerland and furthered his training with a residency in Obstetrics and Gynecology and a Fellowship in Reproductive Endocrinology and Infertility at the University of California at Los Angeles (UCLA). Dr. de Ziegler is a Diplomate of the American Board of Obstetrics and Gynecology. In addition to his work for Ultrast, he is currently director of Reproductive Endocrinology and Infertility at Nyon Hospital, Switzerland. Dr. de Ziegler has authored over 100 publications in the field of Reproductive Medicine and Imaging in peer reviewed journals. He is a member of the editorial board of Human Reproduction, the Journal of Assisted Reproduction and Genetics, and References en Gynecologie.

Howard Levine, Pharm.D. brings a unique and varied background to Ultrast. Dr. Levine received his B.S. in Pharmacy from Oregon State University and Doctor of Pharmacy degree from the State University of New York at Buffalo in 1980. Dr. Levine has held faculty and clinical practice positions at the University of Southern California, Long Island University and Duquesne University instructing students in clinical pharmacology, as well as providing numerous lectures for the continuing education of practitioners. Dr. Levine is the author of numerous publications in laboratory and clinical medicine. Prior to Ultrast, Dr. Levine was with the Medical Department of Pfizer Laboratories specializing in professional communications. Most recently, Dr. Levine was Vice President, Research and Development, for Columbia Laboratories, Inc, where he was responsible for developing several drugs which are currently marketed around the world.